TY - JOUR
T1 - BCG vaccination is associated with reduced malaria prevalence in children under the age of 5 years in sub-Saharan Africa
AU - Berendsen, Mike L.T.
AU - Van Gijzel, Sjors W.L.
AU - Smits, Jeroen
AU - De Mast, Quirijn
AU - Aaby, Peter
AU - Benn, Christine S.
AU - Netea, Mihai G.
AU - Van Der Ven, Andre J.A.M.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Introduction Malaria continues to be a major cause of morbidity and mortality in sub-Saharan Africa (SSA) without effective interventions. Bacillus Calmette-Guérin (BCG) vaccine possesses protective non-specific effects, which extend beyond protection against tuberculosis. This study explores whether BCG is associated with protection against malaria in children under the age of 5 years in SSA. Methods We used data from the Demographic Health Survey programme, including 34 206 children from 13 SSA countries. BCG status was taken from vaccination cards when present; if not, mother's recall was used. Presence of malaria was defined as a positive rapid diagnostic test. Maternally reported presence or absence of fever in the previous 2 weeks defined symptomatic status. Multilevel logistic regression was used to account for the two-stage cluster sampling method. Results Of the 34 206 children, 12 325 (36.0%) children were malaria positive and 29 766 (87.0%) were BCG vaccinated. After correction for relevant child, maternal and household factors, BCG vaccination was associated with a lower malaria prevalence (adjusted OR (aOR)=0.94, 95% CI 0.90 to 0.98), especially among children of whom BCG information was retrieved from a vaccination card (aOR card =0.88, 95% CI 0.82 to 0.94). Restricting the analysis to children from regions with suboptimal BCG coverage increased the association (aOR card =0.81, 95% CI 0.73 to 0.89). We observed an increasingly beneficial association with each mont of age of the child (aOR card =0.996, 95% CI 0.993 to 0.999). BCG associations were similar for asymptomatic (aOR card =0.86, 95% CI 0.81 to 0.92) and symptomatic (aOR card =0.89, 95% CI 0.78 to 1.01) malaria. Conclusions BCG vaccination is associated with protection against malaria. This protection is highest in regions with suboptimal BCG coverage. These results indicate a possible role for timely BCG vaccination in the protection of malaria and its elimination by reducing the transmission reservoir. If confirmed in further research, our findings have substantial implications for global efforts to reduce malaria burden.
AB - Introduction Malaria continues to be a major cause of morbidity and mortality in sub-Saharan Africa (SSA) without effective interventions. Bacillus Calmette-Guérin (BCG) vaccine possesses protective non-specific effects, which extend beyond protection against tuberculosis. This study explores whether BCG is associated with protection against malaria in children under the age of 5 years in SSA. Methods We used data from the Demographic Health Survey programme, including 34 206 children from 13 SSA countries. BCG status was taken from vaccination cards when present; if not, mother's recall was used. Presence of malaria was defined as a positive rapid diagnostic test. Maternally reported presence or absence of fever in the previous 2 weeks defined symptomatic status. Multilevel logistic regression was used to account for the two-stage cluster sampling method. Results Of the 34 206 children, 12 325 (36.0%) children were malaria positive and 29 766 (87.0%) were BCG vaccinated. After correction for relevant child, maternal and household factors, BCG vaccination was associated with a lower malaria prevalence (adjusted OR (aOR)=0.94, 95% CI 0.90 to 0.98), especially among children of whom BCG information was retrieved from a vaccination card (aOR card =0.88, 95% CI 0.82 to 0.94). Restricting the analysis to children from regions with suboptimal BCG coverage increased the association (aOR card =0.81, 95% CI 0.73 to 0.89). We observed an increasingly beneficial association with each mont of age of the child (aOR card =0.996, 95% CI 0.993 to 0.999). BCG associations were similar for asymptomatic (aOR card =0.86, 95% CI 0.81 to 0.92) and symptomatic (aOR card =0.89, 95% CI 0.78 to 1.01) malaria. Conclusions BCG vaccination is associated with protection against malaria. This protection is highest in regions with suboptimal BCG coverage. These results indicate a possible role for timely BCG vaccination in the protection of malaria and its elimination by reducing the transmission reservoir. If confirmed in further research, our findings have substantial implications for global efforts to reduce malaria burden.
KW - bacillus Calmette-Guérin
KW - DHS
KW - heterologous effects
KW - malaria
U2 - 10.1136/bmjgh-2019-001862
DO - 10.1136/bmjgh-2019-001862
M3 - Journal article
C2 - 31798997
AN - SCOPUS:85075171796
VL - 4
JO - BMJ Global Health
JF - BMJ Global Health
IS - 6
M1 - e001862
ER -